Scoop: Boehringer quietly shutters a PhII for one of its top drugs — now under review
Boehringer Ingelheim has quietly shut down a small Phase II study for one of its lead drugs.
The private pharma player confirmed to Endpoints News that it had shuttered a study testing spesolimab as a therapy for Crohn’s patients suffering from bowel obstructions.
A spokesperson for the company tells Endpoints:
Taking into consideration the current therapeutic landscape and ongoing clinical development programs, Boehringer Ingelheim decided to discontinue our program in Crohn’s disease. It is important to note that this decision is not based on any safety findings in the clinical trials.
Premium subscription required
Unlock this article along with other benefits by subscribing to one of our paid plans.